Literature DB >> 35990714

Diagnosis and treatment of hepatitis C virus infection: a tool for engagement with people who inject drugs in Vancouver's Downtown Eastside.

Arshia Alimohammadi1,2, Julie Holeksa1,2, Robyn Parsons1, Rossita Yung1, Neilofar Amiri1, David Truong1, Brian Conway1.   

Abstract

Background: Vancouver's Downtown Eastside (DTES) faces the interrelated challenges of poverty, homelessness, mental health, addiction, and medical issues such as hepatitis C virus (HCV). This study evaluates a new model of engagement with people who inject drugs (PWID) in the DTES.
Methods: Our centre has developed the community pop-up clinic (CPC) to engage vulnerable populations such as PWID. Rapid HCV testing is offered using the OraQuick saliva assay. If a test is positive, immediate medical consultation and an incentivized clinic appointment are offered. At this appointment, an HCV treatment plan is developed, along with a plan for engagement in multidisciplinary care.
Results: In 12 months, 1,283 OraQuick tests were performed at 44 CPCs; 21% of individuals were found to be positive for HCV (68% of whom were PWID). Of individuals positive for HCV antibodies who consulted with the on-site doctor, 50% engaged in care in our clinic-61% of whom have initiated interferon-free directly acting antiviral (DAA) HCV therapy with 100% cured of HCV (per protocol). Individuals who did not engage in care were significantly more likely to be homeless (P < .0001).
Conclusion: CPCs paired with a multidisciplinary model of care address the needs of vulnerable populations such as PWID, particularly in the management of HCV with interferon-free DAA therapies.
Copyright © 2018 Canadian Association for the Study of the Liver.

Entities:  

Keywords:  community outreach; interferon-free DAA HCV therapy; marginalized populations; opioid epidemic

Year:  2018        PMID: 35990714      PMCID: PMC9202795          DOI: 10.3138/canlivj.1.2.002

Source DB:  PubMed          Journal:  Can Liver J        ISSN: 2561-4444


  23 in total

1.  "Silent killer" or benign disease? The dilemma of hepatitis C virus outcomes.

Authors:  K R Hirsch; T L Wright
Journal:  Hepatology       Date:  2000-02       Impact factor: 17.425

2.  Addressing reimbursement disparities for direct-acting antiviral therapies for hepatitis C virus infection is essential to ensure access for all.

Authors:  J Grebely; A Litwin; G J Dore
Journal:  J Viral Hepat       Date:  2016-06-08       Impact factor: 3.728

Review 3.  Treatment of hepatitis C: a systematic review.

Authors:  Anita Kohli; Ashton Shaffer; Amy Sherman; Shyam Kottilil
Journal:  JAMA       Date:  2014-08-13       Impact factor: 56.272

4.  Implementing and scaling up HCV treatment services for people who inject drugs and other high risk groups in Ukraine: An evaluation of programmatic and treatment outcomes.

Authors:  Alyona Mazhnaya; Anna Meteliuk; Tetiana Barnard; Alexei Zelenev; Sergii Filippovych; Frederick L Altice
Journal:  Int J Drug Policy       Date:  2017-08-12

5.  Retention in care: a challenge to survival with HIV infection.

Authors:  Thomas P Giordano; Allen L Gifford; A Clinton White; Maria E Suarez-Almazor; Linda Rabeneck; Christine Hartman; Lisa I Backus; Larry A Mole; Robert O Morgan
Journal:  Clin Infect Dis       Date:  2007-04-23       Impact factor: 9.079

Review 6.  Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis.

Authors:  Bryony Simmons; Jawaad Saleem; Andrew Hill; Richard D Riley; Graham S Cooke
Journal:  Clin Infect Dis       Date:  2016-01-19       Impact factor: 9.079

7.  Estimated prevalence of Hepatitis C Virus infection in Canada, 2011.

Authors:  M Trubnikov; P Yan; C Archibald
Journal:  Can Commun Dis Rep       Date:  2014-12-18

8.  Performance evaluation of the OraQuick hepatitis C virus rapid antibody test.

Authors:  Young Joo Cha; Quehn Park; Eun-Suk Kang; Byung Chul Yoo; Kyoung Un Park; Jin-Wook Kim; Yoo-Sung Hwang; Myung Hee Kim
Journal:  Ann Lab Med       Date:  2013-04-17       Impact factor: 3.464

9.  The hepatitis C cascade of care among HIV infected patients: a call to address ongoing barriers to care.

Authors:  Edward R Cachay; Lucas Hill; David Wyles; Bradford Colwell; Craig Ballard; Francesca Torriani; William C Mathews
Journal:  PLoS One       Date:  2014-07-18       Impact factor: 3.240

Review 10.  Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review.

Authors:  Louisa Degenhardt; Amy Peacock; Samantha Colledge; Janni Leung; Jason Grebely; Peter Vickerman; Jack Stone; Evan B Cunningham; Adam Trickey; Kostyantyn Dumchev; Michael Lynskey; Paul Griffiths; Richard P Mattick; Matthew Hickman; Sarah Larney
Journal:  Lancet Glob Health       Date:  2017-10-23       Impact factor: 26.763

View more
  1 in total

1.  Potential interventions to support HCV treatment uptake among HIV co-infected people in Canada: Perceptions of patients and health care providers.

Authors:  David Ortiz-Paredes; Afia Amoako; David Lessard; Kim Engler; Bertrand Lebouché; Marina B Klein
Journal:  Can Liver J       Date:  2022-02-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.